# Lorazepam Sedation for Critically Ill Children

> **NCT00109395** · PHASE2,PHASE3 · COMPLETED · sponsor: **The Emmes Company, LLC** · enrollment: 179 (actual)

## Conditions studied

- Critical Illness

## Interventions

- **DRUG:** Lorazepam
- **DRUG:** Midazolam
- **DRUG:** Lorazepam CI

## Key facts

- **NCT ID:** NCT00109395
- **Lead sponsor:** The Emmes Company, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2023-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109395, "Lorazepam Sedation for Critically Ill Children". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00109395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*